← Eichor
Condition: Fungoides Mycosis Sezary Syndrome Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Fungoides Mycosis Sezary Syndrome

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Phase 1 · 10 location(s) · SciTech Development, Inc. · NCT04234048Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
Phase 2 · 1 location(s) · University of Michigan Rogel Cancer Center · NCT05956041Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma
Phase 2 · 3 location(s) · City of Hope Medical Center · NCT04930653Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome
Phase 2 · 1 location(s) · Stanford University · NCT04256018ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
Phase N/A · 13 location(s) · Stanford University · NCT02848274Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome.
Phase N/A · 1 location(s) · Lund University Hospital · NCT04904146Novel Flow-cytometry Approaches to Improve the Detection of Tumor Cells in CTCL
Phase N/A · 1 location(s) · Instituto de Investigación Biomédica de Salamanca · NCT06382844A Registry for People With T-cell Lymphoma
Phase N/A · 26 location(s) · Memorial Sloan Kettering Cancer Center · NCT059781413'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell
Phase 1/Phase 2 · 4 location(s) · City of Hope Medical Center · NCT03011814A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Se
Phase N/A · 10 location(s) · City of Hope Medical Center · NCT07003100A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
Phase 2 · 15 location(s) · Prescient Therapeutics, Ltd. · NCT06854653A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma
Phase N/A · 3 location(s) · Peking University First Hospital · NCT06436677Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Phase N/A · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137643Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Phase N/A · 1 location(s) · University of Pittsburgh · NCT00177268Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance
Phase N/A · 6 location(s) · Kyowa Kirin Co., Ltd. · NCT07132567Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
Phase 2 · 8 location(s) · Memorial Sloan Kettering Cancer Center · NCT03587844Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma
Phase N/A · 18 location(s) · Fondazione Italiana Linfomi - ETS · NCT06588868
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.